409 related articles for article (PubMed ID: 36794370)
1. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease.
van Lier YF; Vos J; Blom B; Hazenberg MD
Gut Microbes; 2023; 15(1):2178805. PubMed ID: 36794370
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Fecal Microbiota Transplantation for Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Expanding the Horizon into Pediatrics.
Gray AN; DeFilipp Z
Transplant Cell Ther; 2023 Aug; 29(8):484-491. PubMed ID: 37169290
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal relationship between the gut microbiota variation and diversity and gut graft-versus-host disease (GVHD) following pediatric allogeneic hematopoietic cell transplantation (HCT) - Case series.
Gray AN; Tobin NH; Moore TB; Li F; Aldrovandi GM
Int J Med Microbiol; 2023 May; 313(3):151580. PubMed ID: 37121094
[TBL] [Abstract][Full Text] [Related]
5. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers.
Goeser F; Sifft B; Stein-Thoeringer C; Farowski F; Strassburg CP; Brossart P; Higgins PG; Scheid C; Wolf D; Holderried TAW; Vehreschild MJGT; Cruz Aguilar MR
Eur J Haematol; 2021 Aug; 107(2):229-245. PubMed ID: 33934412
[TBL] [Abstract][Full Text] [Related]
6. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.
Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D
Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579
[TBL] [Abstract][Full Text] [Related]
7. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.
Staffas A; Burgos da Silva M; van den Brink MR
Blood; 2017 Feb; 129(8):927-933. PubMed ID: 27940475
[TBL] [Abstract][Full Text] [Related]
8. The contribution of the intestinal microbiome to immune recovery after HCT.
Wolfe AE; Markey KA
Front Immunol; 2022; 13():988121. PubMed ID: 36059482
[TBL] [Abstract][Full Text] [Related]
9. Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD.
Köhler N; Zeiser R
Front Immunol; 2018; 9():3179. PubMed ID: 30705680
[TBL] [Abstract][Full Text] [Related]
10. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.
DeFilipp Z; Peled JU; Li S; Mahabamunuge J; Dagher Z; Slingerland AE; Del Rio C; Valles B; Kempner ME; Smith M; Brown J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Ballen KK; Sung AD; Dalton TE; Messina JA; Dettmer K; Liebisch G; Oefner P; Taur Y; Pamer EG; Holler E; Mansour MK; van den Brink MRM; Hohmann E; Jenq RR; Chen YB
Blood Adv; 2018 Apr; 2(7):745-753. PubMed ID: 29592876
[TBL] [Abstract][Full Text] [Related]
11. Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis.
Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Ramamoorthy S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C
Cancer Res Commun; 2024 Jun; 4(6):1454-1466. PubMed ID: 38767452
[TBL] [Abstract][Full Text] [Related]
12. Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation.
Schwabkey ZI; Jenq RR
Annu Rev Med; 2020 Jan; 71():137-148. PubMed ID: 31986084
[TBL] [Abstract][Full Text] [Related]
13. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.
Holler E; Butzhammer P; Schmid K; Hundsrucker C; Koestler J; Peter K; Zhu W; Sporrer D; Hehlgans T; Kreutz M; Holler B; Wolff D; Edinger M; Andreesen R; Levine JE; Ferrara JL; Gessner A; Spang R; Oefner PJ
Biol Blood Marrow Transplant; 2014 May; 20(5):640-5. PubMed ID: 24492144
[TBL] [Abstract][Full Text] [Related]
14. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R; Palaniyandi S; Hildebrandt GC
Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
[TBL] [Abstract][Full Text] [Related]
15. Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation.
DeFilipp Z; Hohmann E; Jenq RR; Chen YB
Biol Blood Marrow Transplant; 2019 Jan; 25(1):e17-e22. PubMed ID: 30408565
[TBL] [Abstract][Full Text] [Related]
16. [Gut microbiota and graft-versus-host disease: broad-spectrum antibiotic use increases post-allogeneic hematopoietic stem cell transplant graft-versus-host disease-related mortality].
Shono Y
Rinsho Ketsueki; 2017; 58(7):835-842. PubMed ID: 28781282
[TBL] [Abstract][Full Text] [Related]
17. A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial.
Andermann TM; Fouladi F; Tamburini FB; Sahaf B; Tkachenko E; Greene C; Buckley MT; Brooks EF; Hedlin H; Arai S; Mackall CL; Miklos D; Negrin RS; Fodor AA; Rezvani AR; Bhatt AS
Transplant Cell Ther; 2021 Nov; 27(11):932.e1-932.e11. PubMed ID: 34274493
[TBL] [Abstract][Full Text] [Related]
18. Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation.
Ciernikova S; Kasperova B; Drgona L; Smolkova B; Stevurkova V; Mego M
Blood Rev; 2021 Jul; 48():100790. PubMed ID: 33573867
[TBL] [Abstract][Full Text] [Related]
19. Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation.
Golob JL; Pergam SA; Srinivasan S; Fiedler TL; Liu C; Garcia K; Mielcarek M; Ko D; Aker S; Marquis S; Loeffelholz T; Plantinga A; Wu MC; Celustka K; Morrison A; Woodfield M; Fredricks DN
Clin Infect Dis; 2017 Nov; 65(12):1984-1991. PubMed ID: 29020185
[TBL] [Abstract][Full Text] [Related]
20. Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C
J Clin Oncol; 2023 Dec; 41(34):5306-5319. PubMed ID: 37235836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
